Zydus Cadila has received the final approval from the USFDA to market Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg, and 8 mg. The drug is a selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia. It has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg. The drug is an atypical anti-psychotic used in the treatment of schizophrenia.
Both Doxazosin Tablets and Lurasidone Hydrochloride Tablets will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
